Protestors turn out at BIO; Ganic Pharma launches; Economic development gets spotlight

> Pfizer and Ranbaxy have come to an agreement that will end most of their five-year battle over the generic production of Lipitor, the world's best-selling drug. Report

> Sanofi-Aventis has made a $2 billion bid for Czech generic drugmaker Zentiva. Report

> No annual BIO meeting would be complete without a protest, and PETA obliged this year turned out in San Diego to raise a hue and cry about the use of animals in drug research. Report

> Massachusetts Governor Deval Patrick showed up with $1 billion in biotech incentives, but he's getting a lot of competition from others in the economic development field. Article

> Biomerieux said it has struck a deal to buy Sweden's AB Biodisk, its fourth acquisition in under two years. Report

> GANIC Pharmaceuticals announced its launch backed by Warburg Pincus. Release

At least eight women have died from shock complications of an acute Clostridial infection following a medical abortion using a combination of mifepristone (Mifeprex) and misoprostol (Cytotec). Report

> While Johnson & Johnson and the Red Cross companies apparently thought it worthwhile to expend significant time and energy fighting over their common red cross emblems, they've now decided to call it quits. J&J has officially released all claims against the Red Cross. Report

And Finally...Regular coffee drinking (up to 6 cups per day) is not associated with increased deaths in either men or women. And both caffeinated and decaffeinated coffee consumption is associated with a somewhat smaller rate of death from heart disease. Release

Suggested Articles

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.

In our EuroBiotech roundup this week, a liver disease biotech raises €11 million, Autolus offers stock and Abivax plans midphase trial. 

Merck KGaA spinout iOnctura has raised a €15 million series A round to support an early-phase solid tumor trial of a PI3Kδ inhibitor.